Activating KRAS mutations and PTEN loss reportedly lead to PI3K/AKT pathway activation, independent of EGFR tyrosine kinase status, driving the downstream cancer survival pathways and supporting resistance21. The gene discussed is PIK3CA; the disease is cancer.